Dengue—a mosquito-borne viral disease that has dramatically spread across multiple tropical regions of the world1—is a serious global health burden. An estimated 3.9 billion people worldwide are at risk of infection with dengue viruses,2 and a recent estimate indicates there are 390 million dengue infections per year, of which 96 million manifest clinically (with any severity of disease).3 Even mild dengue may progress to a hemorrhagic form and cause death.
The total annual global cost of dengue illness has been estimated at $8.9 billion during 2013.4 Potential drug sales, assuming 100 percent market share, are estimated to be $338 million per annum.5 The current standard of care is fever and pain relief and transfer to ICUs. Dengue fever vaccines are available, but supply constraints, cost, and other factors limit their impact. 60P remains fully committed to developing potential solutions that complement available vaccines, provide relief to dengue patients, and substantially reduce economic costs associated with the disease.
3-month dengue case notification rate per 100,000, May-July 2022.6
Cases and 1 Million+ deaths in the U.S. from COVID-19 infections
Annual deaths from malaria globally
Travelers to malaria endemic regions per annum
Annual dengue infections globally